Skip to main content
. 2021 Apr 5;11:7490. doi: 10.1038/s41598-021-85328-w

Figure 1.

Figure 1

Upfront steroids decrease the efficacy of immune checkpoint inhibitors in NSCLCBM. (a) Overall Survival differences between those treated with or without upfront steroids. (b) Multivariable analysis of overall survival. (c) Progression-free survival differences between those treated with or without upfront steroids. (d) Multivariable analysis of progression-free survival. (a) and (c) group differences tested with the Wilcoxon test. (b) and (d) estimates from Cox proportional hazards models and the associations tested with effect likelihood ratio tests.